Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy

Completed · Phase 2 · Has a placebo group

Conditions studied: Geographic Atrophy

In brief

The primary objectives of the study are to assess the safety, tolerability and evidence of activity of multiple intravitreal (IVT) injections of pegcetacoplan in subjects with Geographic Atrophy associated with Age-Related Macular Degeneration (AMD).

Key facts

Study ID
NCT02503332
Run by
Apellis Pharmaceuticals, Inc.
People needed
246
Starts
2015-09-24
Expected to finish
2018-01-17
Last updated by the study team
2020-10-06

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.